Improving outcomes for people with skin tumours including melanoma
Improving outcomes for people with skin tumours including melanoma
Improving outcomes for people with skin tumours including melanoma
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Resource implications ..............................................................110<br />
BCC and SCC .......................................................................................111<br />
Melanoma .............................................................................................111<br />
<strong>Improving</strong> Outcomes <strong>for</strong><br />
People <strong>with</strong> Skin Tumours<br />
<strong>including</strong> Melanoma<br />
Contents<br />
Research priorities .....................................................................111<br />
6. Management of special groups ..........................112<br />
Introduction ...................................................................................112<br />
Genetic predisposition ........................................................................112<br />
Organ transplant patients ....................................................................113<br />
Skin lymphomas ..................................................................................114<br />
Skin sarcomas ......................................................................................115<br />
Kaposi’s sarcoma .................................................................................115<br />
Children ................................................................................................116<br />
Recommendations ......................................................................117<br />
Generic recommendations <strong>for</strong> patients <strong>with</strong><br />
uncommon risk factors or rare cancers .............................................117<br />
Genetic predisposition ........................................................................118<br />
Transplant patients ..............................................................................118<br />
Cutaneous lymphoma .........................................................................119<br />
Skin sarcomas ......................................................................................120<br />
Children and young <strong>people</strong> ................................................................120<br />
Anticipated benefits ...................................................................121<br />
Evidence ...........................................................................................121<br />
Genetic predisposition ........................................................................121<br />
Lymphoma ...........................................................................................122<br />
Kaposi’s sarcoma .................................................................................122<br />
Gorlin’s syndrome ...............................................................................123<br />
Transplant patients ..............................................................................123<br />
Children ................................................................................................124<br />
Children and adolescents in clinical trials .........................................124<br />
Measurement .................................................................................124<br />
Guidance on cancer services: <strong>skin</strong> <strong>tumours</strong> <strong>including</strong> <strong>melanoma</strong> 5